HepeX-C (XTL Biopharmaceuticals)
Borgia, G.
Current Opinion in Investigational Drugs 5(8): 892-897
2004
ISSN/ISBN: 1472-4472 PMID: 15600247 Document Number: 577518
XTL Biopharmaceuticals is developing HepeX-C, a combination of two antibodies (HCV-AB68 and HCV-AB65) as a potential therapy for hepatitis C virus infection. By September 2003, phase II trials of HCV-AB68 alone had been conducted and XTL Biopharmaceuticals announced that it planned to conduct a phase I study of the antibody combination.